Chief Accounting Officer
Lisata Therapeutics, Inc. (LSTA)Equibles does not estimate personal net worth.
Get an email with a short summary when Lisata Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get LSTA alertsJames Nisco is recorded as Chief Accounting Officer at Lisata Therapeutics, Inc. (LSTA). The newest filing on record that lists James Nisco as Chief Accounting Officer at Lisata Therapeutics, Inc. (LSTA) is dated October 19, 2026. Lisata Therapeutics, Inc. reported in an 8-K filed April 17, 2024 that James Nisco was appointed Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective April 15, 2024. The proxy statement of Lisata Therapeutics, Inc. reports total compensation of $433,464 for James Nisco in fiscal 2025, including a base salary of $350,000. Disclosed compensation is on record for 3 fiscal years. James Nisco has spoken on 6 earnings calls across 1 company, most recently for Lisata Therapeutics, Inc. on November 6, 2025. Lisata Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lisata Therapeutics, Inc. includes David J. Mazzo (CEO and Board Member), David J. Mazzo, Ph.D. (CEO), Gregory Brown (Chairman) and 7 others.
“On April 15, 2024 (the "Effective Date"), the Board of Directors (the "Board") of Lisata Therapeutics, Inc. (the "Company") appointed James Nisco as the Company's Senior Vice President, Finance and Treasury and Chief Accounting Officer, effective immediately.”
“I'm pleased to join you today to present a summary of our third quarter 2025 financial results. Next, a review of our operating expenses.”
“I'm pleased to join you today to present a summary of our second quarter 2025 financial results starting with revenue for the three months ended june 30th 2025 revenue totaled 70 000 in connection with an upfront license fee related to a research license agreement with catalan inc we did not have any revenue for the…”
“I'm pleased to join you today to present a summary of our first quarter 2025 financial results, starting with operating expenses.”
“I'm pleased to join you today to present a summary of our third quarter 2024 financial results. Starting with operating expenses.”
“I'm pleased to join you today to present a summary of our second quarter 2024 financial results. Starting with operating expenses.”
Source not stated
Start not stated–present
Last confirmed October 19, 2026
Biotechnology · Healthcare
Chief Accounting Officer
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Lisata Therapeutics, Inc. (LSTA) | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $350,000 | $433,464 |
| 2024 | Lisata Therapeutics, Inc. (LSTA) | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $341,938 | $516,166 |
| 2023 | Lisata Therapeutics, Inc. (LSTA) | Senior Vice President, Finance and Treasury and Chief Accounting Officer | $307,526 | $438,554 |
